Clinical trial / 2014
Lutein and zeaxanthin supplementation reduced the risk of late age-related macular degeneration progression.
In a randomized multicenter trial, 4,203 participants aged 50 to 85 years at risk of late age-related macular degeneration (AMD) evaluated lutein/zeaxanthin (10 mg/2 mg) versus no lutein/zeaxanthin or beta carotene. Lutein/zeaxanthin reduced the risk of progression to late AMD compared to no lutein/zeaxanthin (HR 0.90, 95% CI 0.82-0.99; P = 0.04). Compared directly with beta carotene, lutein/zeaxanthin showed a reduced risk of late AMD (HR 0.82, 95% CI 0.69-0.96; P = 0.02).
- Study type
- Randomized controlled trial
- Who was studied
- 4,203 adults aged 50 to 85 years at risk for late AMD
- What was measured
- Progression to late age-related macular degeneration
THE PAPER
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. JAMA Ophthalmol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.